Lexaria Bioscience Corp. Discusses $11 Million Public Offering and 2021 Goals with The Stock Day Podcast
Jan 28, 2021, 01:40 PM
READ FULL PRESS RELEASE: https://stockdaymedia.com/lexaria-bioscience-corp-discusses-11-million-public-offering-and-2021-goals-with-the-stock-day-podcast-lexx-january-18-2021/
The Stock Day Podcast welcomed Lexaria Bioscience Corp. (Nasdaq:LEXX) (CSE:LXX) (“the Company”), a company with the proprietary drug delivery technology, DehydraTECH™, which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream. CEO of the Company, Chris Bunka, joined Stock Day host Everett Jolly.
The Stock Day Podcast welcomed Lexaria Bioscience Corp. (Nasdaq:LEXX) (CSE:LXX) (“the Company”), a company with the proprietary drug delivery technology, DehydraTECH™, which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream. CEO of the Company, Chris Bunka, joined Stock Day host Everett Jolly.